Impact of Abciximab in Elderly Patients with High-Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Interven
- PDF / 188,095 Bytes
- 10 Pages / 504 x 720 pts Page_size
- 18 Downloads / 228 Views
Drugs Aging 2011; 28 (5): 369-378 1170-229X/11/0005-0369/$49.95/0
ª 2011 Adis Data Information BV. All rights reserved.
Impact of Abciximab in Elderly Patients with High-Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention An Observational Registry Study Allan Z. Iversen,1 Soeren Galatius,1 Sune Pedersen,1 Jan K. Madsen1 and Jan S. Jensen1,2 1 Department of Cardiology P, Gentofte University Hospital, Hellerup, Denmark 2 Clinical Institute of Surgery and Internal Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
Abstract
Background: An increasing proportion of patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI) are classified as elderly (aged ‡70 years). The glycoprotein IIb/IIIa inhibitor abciximab is known to reduce adverse outcomes in patients aged
Data Loading...
